Nasus Pharma (NSRX) Non-Current Deferred Tax Liability (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Non-Current Deferred Tax Liability came in at $73000.0 in Q4 2025, down 86.23% YoY from $530000.0 in Q4 2024, and down 86.23% on a QoQ basis from $530000.0 in Q4 2024.
Nasus Pharma (NSRX) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $73000.0 in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 86.23% year-over-year to $73000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73000.0 (down 86.23% YoY) and the FY2025 annual result came in at $73000.0, down 86.23% from the prior year.
- Non-Current Deferred Tax Liability declined to $73000.0 in Q4 2025, from $530000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $530000.0 in Q4 2024 to a low of $73000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 530,000.00 |
| Dec 31, 2024 | 530,000.00 |